Investigators assessed the impact of androgen receptor (AR) gene alterations in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line treatment with AR-targeted agents (ARATs). Lead author of the study, Nishita Tripathi, reported that patients with mCRPC who had AR alterations in circulating tumor DNA (ctDNA) had worse outcomes compared with patients with wild-type AR status. The data were presented at the ESMO Congress 2022. ...
mCRPC
Advertisement
Latest News
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.
177Lu-PSMA-RLT showed efficacy and safety consistent with published evidence in cohort of very old patients with mCRPC.
Karim Fizazi discussed preliminary findings on ODM-208, a first-in-class CYP11A1 inhibitor at ESMO 2022.
Researchers evaluated immune effects of enzalutamide in patients with metastatic castration-resistant prostate cancer on ADT.
Pembrolizumab plus olaparib did not improve survival versus alternating from abiraterone or enzalutamide in mCRPC.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.
A new study has found an association between neurodevelopmental disorders and testicular seminoma.
CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.
Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.
Advertisement
Advertisement
Trending
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
